Asset profile
Carisbamate
Small molecule
Evidence outlook · results not reported
NCT00425282 · Epilepsy, Epilepsy, Focal, Seizure Disorder, Complex Partial Seizures, Epilepsy, Complex...
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT00425282: The study was randomized and double-blind with 566 participants, and its primary endpoint was the clinical measure of change in seizure frequency. However, no results are posted and the registry record does not clearly identify a comparator arm, so the primary endpoint cannot be judged as met or missed.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
66 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 43 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Carisbamate: this drug | Phase 3 | Small molecule | Voltage-gated sodium channel | ||
| Eslicarbazepine Acetate (Aptiom) | Approved | Small molecule | Voltage-gated sodium channel | ||
| Fosphenytoin | Approved | Small molecule | Voltage-gated sodium channel | ||
| Lamotrigine | Approved | Small molecule | Voltage-gated sodium channel | ||
| Oxcarbazepine (Oxtellar XR) | Approved | Small molecule | Voltage-gated sodium channel | ||
| Oxcarbazepine (Trileptal) | Approved | Small molecule | Voltage-gated sodium channel | ||
| Rufinamide | Approved | Small molecule | Voltage-gated sodium channel | ||
| Brivaracetam | Approved | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | ||
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | ||
| Carbamazepine | Approved | Small molecule | Sodium channels | ||
| Cenobamate (Xcopri) | Approved | Small molecule | Sodium channels + GABA-A receptors | ||
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | ||
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | ||
| Diastat | Approved | Combination | GABA-A receptor | ||
| Diazepam (Valium) | Approved | Small molecule | GABA-A receptor | ||
| Diazepam (Valtoco) | Approved | Small molecule | GABA-A receptor |
…and 51 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
February 2027 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.